Treatment choices and outcomes in the National Lung Cancer Audit
Research type
Research Study
Full title
An analysis of treatment choices and outcomes in the UK National Lung Cancer Audit - an analysis of cancer registry and linked clinical datasets
IRAS ID
201523
Contact name
Richard B Hubbard
Contact email
Sponsor organisation
University of Nottingham
Duration of Study in the UK
3 years, 0 months, 0 days
Research summary
The prognosis for people with lung cancer in the UK is poor, and more than half of all people who develop lung cancer die within a year of receiving their diagnosis. There are a number of active treatments which may help people with lung cancer and these include surgery, radiotherapy and chemotherapy. At present surgery offers the best chance of cure for people with lung cancer, but deaths shortly after surgery do occur reflecting the severity of the illness and major nature of the surgery. With this in mind there is a need to improve the evidence base for decisions around who to operate on. The same is true for access to radical radiotherapy to treat lung cancer - though there is even less information available here on early mortality and predictive factors. All chemotherapy options for lung cancer are palliative - but impacts on survival time are important and again decisions around who to treat, particularly for people with advanced disease and significant co-morbid illness are not straight forward. Our research is designed to help with the decision making for all of these treatment options.
In addition we have previously shown that for people with lung cancer there is considerable variation in access to these anticancer treatments and that this variation is not explain by patient level features. An additional element to this research therefore is to examine how the structure of the cancer care pathway impacts on choice of treatment
REC name
London - Camden & Kings Cross Research Ethics Committee
REC reference
16/LO/0503
Date of REC Opinion
21 Mar 2016
REC opinion
Favourable Opinion